» Articles » PMID: 24399866

A Novel Homozygous Mutation at the GAA Gene in Mexicans with Early-onset Pompe Disease

Overview
Journal Acta Myol
Date 2014 Jan 9
PMID 24399866
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Glycogen-storage disease type II, also named Pompe disease, is caused by the deficiency of the enzyme acid alpha-glucosidase, which originates lysosomal glycogen accumulation leading to progressive neuromuscular damage. Early-onset Pompe disease shows a debilitating and frequently fulminating course. To date, more than 300 mutations have been described; the majority of them are unique to each affected individual. Most early-onset phenotypes are associated with frameshift mutations leading to a truncated alpha-glucosidase protein with loss of function. Founder effects are responsible from many cases from few highprevalence world regions. Herein we described two apparently unrelated cases affected with classical early-onset Pompe disease, both pertaining to a small region from Central Mexico (the State of San Luis Potosí), the same novel homozygous frameshift mutation at gene GAA (c.1987delC) was demonstrated in both cases. This GAA gene deletion implies a change of glutamine to serine at codon 663, and a new reading frame that ends after 33 base pairs, which leads to the translation of a truncated protein. This report contributes to widen the knowledge on the effect of pathogenic mutations in Pompe disease. Here we postulate the existence of a founder effect.

Citing Articles

Mutational spectrum and genotype-phenotype correlation in Mexican patients with infantile-onset and late-onset Pompe disease.

Martinez-Montoya V, Sanchez-Sanchez L, Sandoval-Pacheco R, Castro D, Arellano-Valdez C, Avila-Rejon C Mol Genet Genomic Med. 2024; 12(7):e2480.

PMID: 38958145 PMC: 11220502. DOI: 10.1002/mgg3.2480.


A New Mutation Causing Severe Infantile-Onset Pompe Disease Responsive to Enzyme Replacement Therapy.

Moravej H, Amirhakimi A, Showraki A, Amoozgar H, Hadipour Z, Nikfar G Iran J Med Sci. 2018; 43(2):218-222.

PMID: 29749992 PMC: 5936855.

References
1.
Kroos M, Pomponio R, Hagemans M, Keulemans J, Phipps M, DeRiso M . Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype. Neurology. 2007; 68(2):110-5. DOI: 10.1212/01.wnl.0000252798.25690.76. View

2.
Becker J, Vlach J, Raben N, Nagaraju K, Adams E, Hermans M . The African origin of the common mutation in African American patients with glycogen-storage disease type II. Am J Hum Genet. 1998; 62(4):991-4. PMC: 1377028. DOI: 10.1086/301788. View

3.
Ausems M, Verbiest J, Hermans M, Kroos M, Beemer F, Wokke J . Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet. 1999; 7(6):713-6. DOI: 10.1038/sj.ejhg.5200367. View

4.
DiMauro S, Spiegel R . Progress and problems in muscle glycogenoses. Acta Myol. 2011; 30(2):96-102. PMC: 3235878. View

5.
Arad M, Maron B, Gorham J, Johnson Jr W, Saul J, Perez-Atayde A . Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med. 2005; 352(4):362-72. DOI: 10.1056/NEJMoa033349. View